查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088402

心臟標記市場：按產品、技術、檢測方法、應用和最終用戶分類－2026-2032年全球市場預測

Cardiac Marker Market by Product, Technology, Test Mode, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，心臟標記市場將成長至 69.9 億美元，複合年成長率為 8.11%。

主要市場統計數據
基準年 2025 40.4億美元
預計年份：2026年 43.5億美元
預測年份 2032 69.9億美元
複合年成長率 (%) 8.11%

心臟標記市場執行摘要

心臟標記是指在心肌損傷、心臟衰竭、心臟衰竭、血栓症或血流動力學壓力等情況下釋放到血液中的可測量生物標記。高敏肌鈣蛋白I和T仍是評估急性心肌梗塞的核心生物標記物，而B型利鈉肽和N端前B型利鈉激素體則有助於心臟衰竭的診斷和風險分層。其他標誌物，包括肌酸激酶-MB、肌紅蛋白、D-二聚體、C反應蛋白以及新興的多組體學特徵，也在臨床實踐和研究中繼續發揮重要作用。

心臟標記領域的變革性變化

心臟標記領域的研究正從解讀單一檢測結果轉向整合檢驗路徑。高靈敏度肌鈣蛋白檢測法的引入加速了疑似急性冠狀動脈症候群病例中「陽性」和「陰性」判定流程的發展。這包括歐洲臨床實踐中採用的「0/1小時」和「0/2小時」策略，前提是這些策略得到驗證的檢測法和適當的臨床評估的支持。這種轉變提高了人們對極低濃度生物標記分析準確性的期望。

人工智慧對心臟標記的累積影響

人工智慧（AI）並非簡單地取代臨床判斷，而是正在成為心臟標記檢測中一種實用的輔助工具。 AI模型可以整合肌鈣蛋白動力學、利鈉肽水平、心電圖數據、生命徵象、病歷和影像學觀察，以輔助心肌梗塞、補償心臟衰竭和心血管不利事件的風險分層。其價值在於能夠辨識複雜資料集中的模式，並及時回報高風險病例。

關於引入心臟標記的關鍵區域性見解

北美地區憑藉其先進的醫院基礎設施、高敏肌鈣蛋白檢測的廣泛應用以及健全的醫療必要診斷保險報銷體系，仍然是心臟標誌物應用領域極具影響力的地區。美國和加拿大在成熟的急救醫療系統、完善的臨床指南、活躍的心血管研究以及將心臟生物標記檢測結果與電子健康記錄和臨床決策支援系統高度整合等方面都具有優勢。

針對七國集團、歐盟、金磚國家、東協、海灣合作理事會和北約的關鍵群體特定見解。

七國集團（G7）市場正透過研究經費投入、先進的臨床實踐以及對高靈敏度診斷方法的早期應用，塑造全球心臟標記標準。美國、加拿大、日本、德國、法國、義大利和英國正在影響指南制定、監管預期、證據生成、檢查室自動化以及採購標準，這些都將對全球供應商產生影響。

各國對心臟標記的需求洞察

美國在心血管創新、臨床試驗活動以及先進心臟標記檢測流程的引入方面發揮主導作用。同時，加拿大在其公共醫療體系內強調品管的診斷。在墨西哥和巴西，隨著公共和私人醫療體系優先開展非傳染性疾病預防項目，心臟檢測的覆蓋範圍正在擴大，這也增加了對高效急診分診和心臟衰竭管理的需求。

為心臟標記行業的領導者提供的實用建議

產業領導者應優先考慮經臨床檢驗、高靈敏度的檢測方法、清晰的證據包以及可立即投入使用的解決方案，以縮短急診環境中的決策時間。製造商應投資於檢測方法的標準化、批間一致性以及培訓，以幫助臨床醫生解讀不同合併症和患者亞群中的生物標記值。

心臟標記分析的調查方法

本執行摘要基於權威公共資訊來源（包括衛生組織、循環系統學會、監管機構、同行評審的臨床文獻以及全球認可的診斷實踐指南）的二手研究。分析重點關注檢驗的事實，例如心血管疾病的負擔、已確立的生物標記的應用、指南支持的臨床路徑以及檢查室和照護現場的成熟趨勢。

結論：心臟標記診斷的未來

心臟標記產業正處於心血管疾病負擔、急診醫學現代化、檢查室主導和數位轉型等許多領域的交匯點。雖然高靈敏度肌鈣蛋白和利鈉肽檢測仍將是基礎檢測手段，但隨著多標記策略、即時檢測平台和人工智慧輔助決策系統的應用，生物標記驅動型醫療的價值將進一步提升。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：心臟標記市場：依產品分類

  • 裝置
    • 桌面分析儀
    • 手持裝置
    • 免疫分析儀
  • 成套工具
  • 試劑
    • BNP／NT-proBNP
    • CK-MB
    • 肌紅蛋白
    • 肌鈣蛋白
  • 軟體

第8章：心臟標記市場：依技術分類

  • 化學冷光
  • ELISA
  • 螢光免疫分析
  • 免疫檢測

第9章：心臟標記市場：依檢測模式分類

  • 臨床試驗
  • 即時檢測

第10章：心臟標記市場：依應用領域分類

  • 急性冠狀動脈症候群
  • 心臟衰竭
  • 心肌梗塞

第11章：心臟標記市場：依最終用戶分類

  • 門診部
  • 診斷檢查室
  • 醫院
  • 研究所

第12章：心臟標記市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：心臟標記市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：心臟標記市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • Aehealth Limited
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biomerieux SA
  • Biosynth Ltd.
  • Cliawaived, Inc.
  • Danaher Corporation
  • DiaSorin SPA
  • Fujirebio Diagnostics, Inc.
  • HyTest Ltd.
  • Laboratory Corporation of America Holdings
  • Merck KGaA
  • MESO SCALE DIAGNOSTICS, LLC.
  • PerkinElmer Inc.
  • Quidel Corporation
  • Randox Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Sanner GmbH
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Tosoh India Pvt. Ltd.
  • Trinity Biotech PLC
Product Code: MRR-034230D3E2D1

The Cardiac Marker Market is projected to grow by USD 6.99 billion at a CAGR of 8.11% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.04 billion
Estimated Year [2026] USD 4.35 billion
Forecast Year [2032] USD 6.99 billion
CAGR (%) 8.11%

Cardiac Marker Market Executive Summary

Cardiac markers are measurable biomarkers released into blood during myocardial injury, heart failure, inflammation, thrombosis, or hemodynamic stress. High-sensitivity cardiac troponin I and T remain the central biomarkers for acute myocardial infarction assessment, while B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide support heart failure diagnosis and risk stratification. Other markers, including creatine kinase-MB, myoglobin, D-dimer, C-reactive protein, and emerging multi-omic signatures, continue to serve defined clinical and research roles.

The strategic importance of the cardiac marker landscape is grounded in global disease burden. The World Health Organization identifies cardiovascular diseases as the leading cause of death worldwide, responsible for an estimated 17.9 million deaths annually. This clinical reality is driving demand for faster, more sensitive, and more accessible cardiac biomarker testing across emergency departments, intensive care units, outpatient clinics, and point-of-care settings.

For industry leaders, the cardiac marker market is shaped by three core priorities: diagnostic accuracy, turnaround time, and clinical workflow integration. Competitive differentiation increasingly depends on validated assay performance, compatibility with guideline-based algorithms, connectivity with hospital information systems, and the ability to support earlier decision-making without increasing false positives or unnecessary downstream procedures.

Transformative Shifts in the Cardiac Marker Landscape

The cardiac marker landscape is shifting from single-test interpretation toward integrated diagnostic pathways. High-sensitivity troponin assays have enabled accelerated rule-in and rule-out protocols for suspected acute coronary syndrome, including 0/1-hour and 0/2-hour strategies used in European clinical practice when supported by validated assays and appropriate clinical assessment. This shift has raised expectations for analytical precision at very low biomarker concentrations.

Care delivery is also moving beyond centralized laboratories. Point-of-care cardiac marker platforms are expanding in emergency, ambulance, rural, and ambulatory environments where rapid results can influence triage decisions. However, adoption depends on maintaining laboratory-comparable quality, robust quality control, operator training, and connectivity that allows results to be documented, audited, and interpreted in context.

Another major transformation is the move toward multi-marker risk assessment. Troponin and natriuretic peptides are increasingly interpreted alongside renal function, age, sex, electrocardiography, imaging, and clinical risk scores. This trend supports more personalized cardiovascular diagnostics but also requires manufacturers and providers to address standardization, reference intervals, and clinical education.

Cumulative Impact of Artificial Intelligence on Cardiac Markers

Artificial intelligence is becoming a practical enabler in cardiac marker testing rather than a standalone substitute for clinical judgment. AI models can combine troponin kinetics, natriuretic peptide values, electrocardiogram data, vital signs, medical history, and imaging findings to support risk stratification for myocardial infarction, heart failure decompensation, and adverse cardiovascular events. The value lies in pattern recognition across complex datasets and timely escalation of high-risk cases.

In laboratory operations, AI can support anomaly detection, instrument utilization planning, reflex testing protocols, and quality assurance. For manufacturers, machine learning is being used in assay development, signal processing, and biomarker discovery, including proteomic and metabolomic approaches that may identify earlier indicators of cardiovascular stress or injury.

The cumulative impact of AI will depend on clinical validation, transparent model governance, cybersecurity, and regulatory compliance. Algorithms used with cardiac biomarkers must demonstrate performance across diverse populations because troponin and natriuretic peptide interpretation can be influenced by age, sex, renal disease, chronic heart failure, sepsis, and structural heart disease.

Key Regional Insights for Cardiac Marker Adoption

North America remains a highly influential region for cardiac marker adoption due to advanced hospital infrastructure, broad use of high-sensitivity troponin testing, and strong reimbursement pathways for medically necessary diagnostics. The United States and Canada benefit from mature emergency medicine systems, established clinical guidelines, significant cardiovascular research activity, and growing integration of cardiac biomarker results with electronic health records and clinical decision support.

Europe shows strong alignment with evidence-based cardiac biomarker protocols, particularly through widespread adoption of high-sensitivity troponin algorithms and heart failure biomarker testing. European Union countries emphasize regulatory rigor under in vitro diagnostic rules, while the United Kingdom, Germany, France, Italy, and Spain continue to support advanced laboratory medicine networks, quality assurance programs, and standardized cardiovascular care pathways.

Asia-Pacific is expanding as China, India, Japan, South Korea, Australia, and ASEAN healthcare systems invest in emergency care, chronic disease management, and diagnostic access. Latin America, led by Brazil and Mexico, is improving cardiac diagnostic capacity while managing affordability and access gaps. The Middle East, especially GCC markets, is investing in tertiary care and cardiology centers, while Africa presents long-term opportunity tied to point-of-care access, workforce training, and health system strengthening.

Key Group Insights Across G7, EU, BRICS, ASEAN, GCC, and NATO

G7 markets shape global cardiac marker standards through research funding, advanced clinical practice, and early adoption of high-sensitivity assays. The United States, Canada, Japan, Germany, France, Italy, and the United Kingdom influence guideline development, regulatory expectations, evidence generation, laboratory automation, and procurement standards that affect global suppliers.

The European Union is central to assay quality, conformity assessment, and cross-border market access under strengthened in vitro diagnostic regulation. NATO countries represent a large base of advanced healthcare systems where emergency readiness, hospital interoperability, reliable diagnostic supply, and supply chain resilience are important procurement factors for cardiac marker testing.

BRICS markets are increasingly important because China, India, Brazil, Russia, and South Africa combine large cardiovascular disease burdens with expanding diagnostic infrastructure. ASEAN countries are prioritizing access, affordability, and decentralized testing, while GCC markets are investing in high-acuity cardiac care, preventive screening, digital health integration, and specialized cardiovascular centers.

Key Country Insights for Cardiac Marker Demand

The United States leads in cardiovascular innovation, clinical trial activity, and adoption of advanced cardiac marker workflows, while Canada emphasizes quality-controlled diagnostics within publicly funded care. Mexico and Brazil are expanding access to cardiac testing as noncommunicable disease programs gain priority across public and private health systems, with growing need for efficient emergency triage and heart failure management.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain strong laboratory medicine capabilities and guideline-driven use of troponin and natriuretic peptide testing. Russia continues to represent a sizable cardiovascular diagnostics environment shaped by hospital modernization, regional access variation, and the need to strengthen timely cardiac risk assessment across diverse care settings.

China and India are central growth engines because of large patient populations, rising cardiovascular risk factors, and expanding hospital networks. Japan, South Korea, and Australia demonstrate mature adoption of high-quality diagnostics, strong technology infrastructure, and demand for precise, efficient cardiovascular care pathways supported by laboratory automation, digital connectivity, and aging-population care needs.

Actionable Recommendations for Cardiac Marker Industry Leaders

Industry leaders should prioritize clinically validated high-sensitivity assays, clear evidence packages, and workflow-ready solutions that reduce time to decision in acute care. Manufacturers should invest in assay standardization, lot-to-lot consistency, and education that helps clinicians interpret biomarker values across comorbidities and patient subgroups.

Diagnostic companies and healthcare providers should expand connectivity between analyzers, laboratory information systems, electronic health records, and clinical decision support tools. Point-of-care deployment should be paired with governance, operator competency programs, external quality assessment, and cybersecurity controls to support safe, auditable, and scalable use.

Commercial strategies should be region-specific. Mature markets require differentiation through clinical evidence, automation, and digital integration, while emerging markets require affordability, service reliability, training, and scalable distribution models. Partnerships with hospitals, emergency networks, academic centers, and public health agencies can accelerate adoption.

Research Methodology for Cardiac Marker Analysis

This executive summary is built on secondary research from authoritative public sources, including global health agencies, cardiovascular societies, regulatory bodies, peer-reviewed clinical literature, and recognized diagnostic practice guidelines. The analysis emphasizes verified facts such as cardiovascular disease burden, established biomarker use, guideline-supported clinical pathways, and documented trends in laboratory and point-of-care diagnostics.

The methodology combines disease-burden assessment, technology trend analysis, regional healthcare infrastructure review, and regulatory environment evaluation. Insights were synthesized to identify demand drivers, adoption barriers, clinical workflow implications, and strategic opportunities across regions, economic groups, and priority countries.

No unsupported market-size figures or unverified forecasts are used. Conclusions are based on data-backed industry signals, including the clinical role of high-sensitivity troponin, natriuretic peptide testing for heart failure, growth of decentralized diagnostics, and increasing use of digital decision support in cardiovascular care.

Conclusion: The Future of Cardiac Marker Diagnostics

The cardiac marker industry is positioned at the intersection of cardiovascular disease burden, emergency care modernization, laboratory innovation, and digital transformation. High-sensitivity troponin and natriuretic peptide testing will remain foundational, while multi-marker strategies, point-of-care platforms, and AI-enabled decision support expand the value of biomarker-driven care.

Success will depend on more than analytical performance. Market leaders must deliver clinically validated, interoperable, and quality-controlled solutions that fit real-world workflows and support equitable access across mature and emerging healthcare systems.

Organizations that align product development with guideline-based medicine, regional affordability needs, quality assurance, and digital integration will be best positioned to address long-term opportunities in the global cardiac marker market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cardiac Marker Market, by Product

  • 7.1. Instruments
    • 7.1.1. Benchtop Analyzer
    • 7.1.2. Handheld Devices
    • 7.1.3. Immunoanalyzer
  • 7.2. Kits
  • 7.3. Reagents
    • 7.3.1. Bnp/Nt-ProBNP
    • 7.3.2. Ck-Mb
    • 7.3.3. Myoglobin
    • 7.3.4. Troponin
  • 7.4. Software

8. Cardiac Marker Market, by Technology

  • 8.1. Chemiluminescence
  • 8.2. Elisa
  • 8.3. Fluorescence Immunoassay
  • 8.4. Immunoassay

9. Cardiac Marker Market, by Test Mode

  • 9.1. Laboratory Testing
  • 9.2. Point Of Care Testing

10. Cardiac Marker Market, by Application

  • 10.1. Acute Coronary Syndrome
  • 10.2. Heart Failure
  • 10.3. Myocardial Infarction

11. Cardiac Marker Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals
  • 11.4. Research Laboratories

12. Cardiac Marker Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Cardiac Marker Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cardiac Marker Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. Aehealth Limited
  • 16.3. Becton, Dickinson and Company
  • 16.4. Bio-Rad Laboratories, Inc.
  • 16.5. Biomerieux SA
  • 16.6. Biosynth Ltd.
  • 16.7. Cliawaived, Inc.
  • 16.8. Danaher Corporation
  • 16.9. DiaSorin S.P.A.
  • 16.10. Fujirebio Diagnostics, Inc.
  • 16.11. HyTest Ltd.
  • 16.12. Laboratory Corporation of America Holdings
  • 16.13. Merck KGaA
  • 16.14. MESO SCALE DIAGNOSTICS, LLC.
  • 16.15. PerkinElmer Inc.
  • 16.16. Quidel Corporation
  • 16.17. Randox Laboratories Ltd.
  • 16.18. Roche Diagnostics Ltd.
  • 16.19. Sanner GmbH
  • 16.20. Siemens Healthineers AG
  • 16.21. Thermo Fisher Scientific Inc.
  • 16.22. Tosoh India Pvt. Ltd.
  • 16.23. Trinity Biotech PLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIAC MARKER MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CARDIAC MARKER MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CARDIAC MARKER MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CARDIAC MARKER MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIAC MARKER MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL CARDIAC MARKER MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CARDIAC MARKER MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CARDIAC MARKER MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CARDIAC MARKER MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CARDIAC MARKER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CARDIAC MARKER MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CARDIAC MARKER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CARDIAC MARKER MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CARDIAC MARKER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BENCHTOP ANALYZER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BENCHTOP ANALYZER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BENCHTOP ANALYZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HANDHELD DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HANDHELD DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HANDHELD DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNOANALYZER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNOANALYZER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNOANALYZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BNP/NT-PROBNP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BNP/NT-PROBNP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BNP/NT-PROBNP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CK-MB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CK-MB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CK-MB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MYOGLOBIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MYOGLOBIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MYOGLOBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TROPONIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TROPONIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TROPONIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHEMILUMINESCENCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CHEMILUMINESCENCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHEMILUMINESCENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ELISA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ELISA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ELISA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FLUORESCENCE IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FLUORESCENCE IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FLUORESCENCE IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LABORATORY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LABORATORY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LABORATORY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ACUTE CORONARY SYNDROME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HEART FAILURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEART FAILURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MYOCARDIAL INFARCTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MYOCARDIAL INFARCTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MYOCARDIAL INFARCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARDIAC MARKER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA CARDIAC MARKER MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA CARDIAC MARKER MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE CARDIAC MARKER MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST CARDIAC MARKER MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA CARDIAC MARKER MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CARDIAC MARKER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN CARDIAC MARKER MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GCC CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 138. GCC CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 139. GCC CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 140. GCC CARDIAC MARKER MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 141. GCC CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. GCC CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. GCC CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION CARDIAC MARKER MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS CARDIAC MARKER MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. G7 CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. G7 CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 163. G7 CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 164. G7 CARDIAC MARKER MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 165. G7 CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. G7 CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 167. G7 CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. G7 CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. NATO CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. NATO CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 171. NATO CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 172. NATO CARDIAC MARKER MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 173. NATO CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. NATO CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. NATO CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL CARDIAC MARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES CARDIAC MARKER MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. CANADA CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. CANADA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 188. CANADA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 189. CANADA CARDIAC MARKER MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 190. CANADA CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. CANADA CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 192. CANADA CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. CANADA CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. MEXICO CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. MEXICO CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 196. MEXICO CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 197. MEXICO CARDIAC MARKER MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 198. MEXICO CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. MEXICO CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 200. MEXICO CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. MEXICO CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. BRAZIL CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. BRAZIL CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 204. BRAZIL CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 205. BRAZIL CARDIAC MARKER MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 206. BRAZIL CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. BRAZIL CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 208. BRAZIL CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. BRAZIL CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED KINGDOM CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED KINGDOM CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED KINGDOM CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED KINGDOM CARDIAC MARKER MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED KINGDOM CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED KINGDOM CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED KINGDOM CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED KINGDOM CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. GERMANY CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. GERMANY CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 220. GERMANY CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 221. GERMANY CARDIAC MARKER MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 222. GERMANY CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. GERMANY CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 224. GERMANY CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. GERMANY CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. FRANCE CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. FRANCE CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 228. FRANCE CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 229. FRANCE CARDIAC MARKER MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 230. FRANCE CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. FRANCE CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 232. FRANCE CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. FRANCE CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. RUSSIA CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. RUSSIA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 236. RUSSIA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 237. RUSSIA CARDIAC MARKER MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 238. RUSSIA CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. RUSSIA CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 240. RUSSIA CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. RUSSIA CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. ITALY CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. ITALY CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 244. ITALY CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 245. ITALY CARDIAC MARKER MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 246. ITALY CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. ITALY CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 248. ITALY CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. ITALY CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. SPAIN CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. SPAIN CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 252. SPAIN CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 253. SPAIN CARDIAC MARKER MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 254. SPAIN CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. SPAIN CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 256. SPAIN CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 257. SPAIN CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA CARDIAC MARKER MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. INDIA CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 267. INDIA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 268. INDIA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 269. INDIA CARDIAC MARKER MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 270. INDIA CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. INDIA CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 272. INDIA CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 273. INDIA CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. JAPAN CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. JAPAN CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 276. JAPAN CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 277. JAPAN CARDIAC MARKER MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 278. JAPAN CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. JAPAN CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 280. JAPAN CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 281. JAPAN CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. AUSTRALIA CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. AUSTRALIA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 284. AUSTRALIA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 285. AUSTRALIA CARDIAC MARKER MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 286. AUSTRALIA CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 287. AUSTRALIA CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 288. AUSTRALIA CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 289. AUSTRALIA CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 290. SOUTH KOREA CARDIAC MARKER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 291. SOUTH KOREA CARDIAC MARKER MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 292. SOUTH KOREA CARDIAC MARKER MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 293. SOUTH KOREA CARDIAC MARKER MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 294. SOUTH KOREA CARDIAC MARKER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 295. SOUTH KOREA CARDIAC MARKER MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 296. SOUTH KOREA CARDIAC MARKER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 297. SOUTH KOREA CARDIAC MARKER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)